ANA CAROLINA CABALLERO GONZÁLEZ

Josep Carreras Leukaemia Research Institute

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (13)

Collaborators (5)

Miguel Arguello-Tomas

Josep Carreras Leukaemia Research Institute

Carmen Álvarez Fernández

Institut de Recerca Sant Pau

Javier Briones Meijide

University of Barcelona

albert esquirol

Silvana Novelli

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

ANA CAROLINA CABALLERO GONZÁLEZ

Research Interests

Explore related searches

Contact this professor

Articles (13)

Collaborators (5)

Miguel Arguello-Tomas

Carmen Álvarez Fernández

Javier Briones Meijide

albert esquirol

Silvana Novelli

Make your next move.

ANA CAROLINA CABALLERO GONZÁLEZ

Research Interests

Explore related searches

Contact this professor

Articles (13)

Treatment outcomes in patients with large B-cell lymphoma after progression to chimeric antigen receptor T-cell therapy.

Sequence matters: Total body irradiation (TBI)‐based myeloablative conditioning with post‐transplant cyclophosphamide may reduce the early nonrelapse mortality compared with pretransplant cyclophosphamide plus <scp>TBI</scp>

Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced-Doses of Post-Transplant Cyclophosphamide: challenges and review of the literature.

Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study.

Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.

Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.

Correction to: High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion.

Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience.

Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study

Erratum: Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma.

High CAR intensity of expression confers enhanced antitumor effect against lymphoma without functional exhaustion.

CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure.

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma.

Collaborators (5)

Miguel Arguello-Tomas

Carmen Álvarez Fernández

Javier Briones Meijide

albert esquirol

Silvana Novelli

Make your next move.